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The target of rapamycin (TOR) signaling pathway regulates cell growth and proliferation, however the extent to which TOR signaling mediates
particular organogenesis programs remains to be determined. Here we report an examination of TOR signaling during zebrafish development,
using a combination of small molecule treatment and morpholino-mediated gene knockdown. First, we amplified and sequenced the full-length
cDNA for the zebrafish TOR ortholog (ztor). By in situ hybridization, we found that ztor is expressed ubiquitously in the early embryo, but
displays a dynamic pattern in the gut between 48 and 72 h post-fertilization (hpf). Treatment of zebrafish embryos with rapamycin induced only a
mild general developmental delay up to 72 hpf, but digestive tract development became arrested at the primitive gut tube stage. Rapamycin
inhibited intestinal epithelial growth, morphogenesis and differentiation. Using morpholino-mediated gene knockdown of TOR pathway
components, we show that this effect is mediated specifically by the rapamycin-sensitive TOR complex 1 (TORC1). Thus, in addition to
regulating cell growth and proliferation, TOR signaling controls the developmental program guiding epithelial morphogenesis in the vertebrate
intestine.
© 2006 Elsevier Inc. All rights reserved.Keywords: Intestine; Target of rapamycin; mTOR; TORC1; Zebrafish; Organogenesis; Morphogenesis; Intestinal developmentIntroduction
Organ development requires coordination between multiple
cellular processes to yield an organ of the proper size and tissue
architecture. The mechanisms by which organs are guided to a
particular size are not well understood, but this knowledge is
critical for treating a wide array of diseases from organ failure to
cancer. The zebrafish is an excellent model for vertebrate
organogenesis since development can be monitored in real time
in the live embryo (Fishman, 2001). Furthermore, it is amenable
to molecular manipulation by morpholino-mediated gene
knockdown, and to studying the effects of small molecules on
specific developmental processes (Peterson and Fishman,
2004).
We are particularly interested in understanding how the
intestine develops, and the zebrafish provides a highly tractable⁎ Corresponding author. Fax: +1 414 456 6632.
E-mail address: alanmayer@mac.com (A.N. Mayer).
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doi:10.1016/j.ydbio.2006.11.030model system for its study. The primitive gut tube is formed
from the endoderm between 32 and 40 h post-fertilization
(Wallace et al., 2005). The epithelial cells become progressively
more polarized and begin to express intestine-specific genes
between 66 and 84 hpf, with folds of mucosa emerging at
96 hpf, foreshadowing the formation of villi over the next
several days. By 120 hpf, it begins to perform its vital function
of nutrient absorption. Thus, between 48 and 120 hpf, the
intestinal epithelium can be observed to expand by nearly an
order of magnitude, making it a useful model for the study of
organ growth and morphogenesis.
Forward genetic analysis of gut development in the zebrafish
genome has identified a number of genes required for intestinal
growth. The nil per os (npo) mutation induces arrest of
intestinal development at the primitive gut tube stage and
disrupts a conserved RNA-binding protein involved in proces-
sing of pre-ribosomal RNA (Jin et al., 2002; Mayer and
Fishman, 2003; Saijou et al., 2004). A number of insertional
mutants also show defective intestinal growth, but most of these
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Interestingly, like npo, many of these affect genes directly
involved in protein biosynthesis or other anabolic function.
Examples include several amino acyl t-RNA synthetases,
ribosomal proteins, nucleolar factors involved in ribosome
biogenesis and polyamine biosynthesis. These genetic data thus
suggest that the regulation of translation might play an
important role in the transition of the primitive gut endoderm
into mature intestine. In a separate line of investigation,
numerous studies have pointed to intestinal epithelial cells as
particularly sensitive to regulation by amino acids (reviewed in
Naomoto et al., 2005).
The target of rapamycin (TOR) plays a central role in the
regulation of cell growth and proliferation in all eukaryotic
species examined via its regulation of the cell’s growth
machinery and protein biosynthesis in particular (Wullschleger
et al., 2006). TOR kinase is the catalytic core of a multiprotein
complex that interprets a variety of inputs – nutritional status,
growth factor signaling, cellular stress – and regulates the cell’s
metabolic machinery in response. The role of TOR in
embryonic development has been probed in C. elegans and
Drosophila, and to a lesser extent in the mouse due to early
lethality. In C. elegans, RNAi-mediated knockdown and genetic
mutations result in growth arrest and intestinal degeneration
(Long et al., 2002). In Drosophila, mutations in dTOR exhibit
slowed larval growth developmental delay (Oldham et al.,
2000). Conversely, mutation of the dTOR inhibitors dTSC1 or
dTSC2 leads to organ hypertrophy (Gao et al., 2002). A
spontaneous mutation known as flathead encodes a hypo-
morphic allele of TOR, and these mice arrest their development
around E12.5 and display widespread reduction of cell
proliferation (Hentges et al., 2001). Mice rendered null for
TOR arrest at the perimplantation stage (Gangloff et al., 2004;
Murakami et al., 2004). These studies support an essential early
role for TOR during mammalian development, then perhaps a
distinct later role in regulating organ and body size. Consistent
with this idea, human genetic defects that are associated with
unregulated TOR activity manifest as abnormal growth.
Examples of such conditions include intestinal polyposis
syndromes Peutz–Jeghers and Banayan–Riley–Ruvalcaba,
the systemic hamartoma syndrome tuberous sclerosis and
other overgrowth syndromes (Inoki et al., 2005).
In this study, we sought to determine the role of TOR
signaling during zebrafish development. We used rapamycin
treatment and morpholino-mediated gene knockdown toTable 1
Morpholino and RT-PCR oligonucleotide sequences
Gene Accession # Morpholino sequence
S6 kinase NM_212786 296-EI cagtcttcaacttacgtgaacaaga
Start gtccggttcctcttcgcaaacattc
ztor BC091880 2270-EI ggtttgacacattaccctgagcatg
2221-IE cgctgaatactgctcaaaagaaaca
raptor XM_684221 EI-2 atggatggatggatgctcacctatc
Start gttttttcctctgcgtctaccattg
rictor XM_685234 EI-2 agtgcaataaaacgtggtacagacc
Start tcggatgctgaccgccatctttaccmanipulate the TOR pathway in the zebrafish. Our findings
suggest that signaling through TORC1 controls a critical step
during the endoderm–intestine transition.
Materials and methods
Fish stocks and embryo culture
The TUAB, TL and the Gut-GFP transgenic fish line were used in this study.
Zebrafish embryos were maintained and mated as described in Westerfield
(1995). Embryos were collected and raised at 28.5 °C. Larvae were staged
according to morphological features described in Kimmel et al. (1995). Live
photographs at different developmental stages were captured using a Leica
MZFLIII dissecting microscope.
Morpholino knockdowns
All morpholinos, at 100–400 μM, were microinjected into 1- to 4-cell stage
embryos. Morpholinos antisense oligonucleotides were designed corresponding
to exon–intron junctions of zebrafish genomic sequences and splicing
interference was detected by RT-PCR across the targeted exon. Sequences for
the morpholinos and RT-PCR primers are given in Table 1.
Histology and morphometry
For histology, embryos were fixed in 4% paraformaldehyde in PBS for 2 h at
room temperature or overnight at 4 °C. Embryos were then washed in PBS,
dehydrated in ethanol and then embedded in glycol methacrylate, JB-4
(Polysciences). Four-micron cross-sections were stained with hematoxylin and
eosin. Sections were analyzed by using a Zeiss Axioplan microscope, captured
using a Q-imaging digital camera and OpenLab 4.02 (Improvision). Morpho-
metric analysis was performed using OpenLab.
Cross-sections were chosen based on the following anatomical landmarks:
50 μm after the common bile duct for the anterior, after the appearance of
pancreatic islets for the midgut and at the yolk extension AP levels for the
posterior. Cell counts were obtained typically from 4 to 6 embryos. Per section
cells were counted and the gut circumference was measured in microns. Average
cellwidthwas determinedbydividing the circumference by total cell number.Cell
height was measured as the number of microns across the nucleus from basal to
apical surface (average of five cells per section). Themean and standard deviation
of numbers collected from control and rapamycin-treated embryos were graphed.
Statistical analysis was preformed using a two-tailed t-test (Microsoft Excel).
Drug treatment
A stock solution of rapamycin (Sigma) in DMSO was added to the embryo
media at a final concentration of 400 nM. FK506 (AntibioticsPlus) was
dissolved in DMSO and used at indicated concentrations. Drug-containing
media were replaced every 24 h. In some experiments, embryos at later
developmental stages were injected with drug to avoid problems with drug
penetration. Injections into the circulation consisted of 13 nl of 60 μM
rapamycin plus 2.5 mg/ml rhodamine dextran (to track the effectiveness of thePrimers sequence (5′–3′) bp
Forward-GATGACTCCATGATTGAGGA
Reverse-CAGTCCATGTAAATGGTCTA
470
Forward-GAGTTCATGTTCCTGCTG
Reverse-CCATCCAATGTAGCATTGG
1200
Forward-ACAGTGAGTGTGGCTCTAG
Reverse-CCT CCT TGG CAT TTC TGC GTA G
270
Forward-GTGGCCAAACAACAAGGAGT
Reverse-CCTGATGAGGTAGCGGAGAG
203
Table 2
Primer pairs for in situ probe templates
Gene Primers (5′–3′)
ztor Forward1-TGGTGTTACGAGAACTGGCTGTC
Reverse1-TGAAAGTGTGAGGCTGGAAGGC
Forward2-TTCTGAACAGCGAGCACAAGG
Reverse2-AGTTGAGCAGCACCTCCAGTAGAG
Forward3-GCTTTTTGGCTTGGTGAACACTC
Reverse3-TCCAGGCTTTTTGTGCGTTG
villin Forward-TATAGTTTCCTGCAGAGAAGCTGGT
Reverse-GGGTGCAGTAGTCTCCGGGTGT
raptor Forward1-CAGATGAAAACAGTGAGTGTGGCTC
Reverse1-CAAACCTCTCGGTAGGACATTCC
Forward2-TCACTACGCAGAAATGCCAAGG
Reverse2-GTTCAGCAAAGAATGGACTGTGC
rictor Forward1-GGGCACTCTGAGGAAAAGTTTGG
Reverse1-TGCTGTGTCTGGATTGTGTCTGTAG
Forward2-CTCGCATTGCTGCTTTCTGC
Reverse2-CATCTGTTCCTCTTTGTTGTTCCG
Forward3-TCCACCCCTCCCTTTCTCATAGTG
Reverse3-GACAGTTCTCCTCAGTGTGCTCTTG
503K. Makky et al. / Developmental Biology 303 (2007) 501–513injection). Embryos were scored for successful injection by rhodamine
fluorescence to determine if the injected solution had entered the circulation.
These positive embryos were subjected for the final analysis.
RT-PCR
Total RNAwas extracted from zebrafish embryos using Trizol (Invitrogen).
Reverse transcription was performed using oligo (dT)20 and SuperScript™ II.
PCR reactions used Taq polymerase from Qiagen and contained 5% of the
reverse transcription.
5-Bromo-2′-deoxy-uridine (BrdU) labeling
Rapamycin treatment. TL strain embryos at 24 hpf were treated with 400 nM
rapamycin while the remaining half were treated with DMSO carrier. Embryos
were placed in fresh media every 24 h and allowed to grow at 28 °C.
BrdU injection. All embryos were dechorionated and injected with 10 nl of
5 mM BrdU (Roche) with 2.5 mg/ml rhodamine dextran at either 51 or 72 hpf
then incubated at 28 °C for 90 min. Embryos were scored for successful
injection by rhodamine fluorescence to determine if the injected solution had
entered the circulation. Selected embryos were fixed overnight at 4 °C in 4%
PFA and stored in methanol at −20 °C.
Anti-BrdU immunostaining. Embryos were rehydrated in a graded methanol
PBT series. For permeabilization, embryos were digested using proteinase K
treatment for 30 min (30 μg/ml for 51 hpf, rapamycin-treated and untreated,
and 72 hpf rapamycin-treated; 80 μg/ml, 72 hpf untreated). Embryos were
postfixed in 4% PFA for 20 min then incubated in 2 N HCl for 1 h to denature
the DNA. Embryos were blocked with blocking solution (10% sheep serum,
1% BSA, in PBT) for 30 min. Embryos were incubated in primary anti-BrdU
antibody (Roche 117037; 6 μg/ml in blocking solution) overnight at 4 °C then
in secondary AlexFluor564-conjugated goat anti-mouse (Molecular Probes)
for 1 h.
Mounting and sectioning. Embryos were fixed in 4% PFA for 20 min,
dehydrated in graded ethanol and embedded in JB-4. Blocks were sectioned at
4 μm and counter-stained with DAPI.
Cell counting and analysis. Gut epithelial cells were identified in the DAPI-
stained sections and used to calculate the total cell number; BrdU labeled cells
were counted for each embryo and the fraction of BrdU/total number was
calculated for each embryo (n=8 embryos per treatment). These numbers were
used to calculate the mean and standard deviation for both rapamycin-treated
and control groups. Differences between the two groups were analyzed using a
two-tailed t-test and unequal variances (Microsoft Excel).
RNA in situ hybridization
Probe synthesis and whole-mount RNA in situ hybridization were carried
out as described (Mayer and Fishman, 2003). Probe for ifabp was as described
(Mayer and Fishman, 2003). Probes were generated by RT-PCR using gene
specific forward and reverse primers, listed in Table 2, and using 4 dpf randomly
primed total RNA. Reverse primers were synthesized with a T7 polymerase
recognition sequence in the 5′ tail.
Immunostaining and histochemistry
Whole-mount α6F staining
Embryos at 4.5 dpf were fixed in DENT’s (20% DMSO/80% methanol) for
2 h to overnight and blocked for 1 h at room temperature in blocking buffer
(10% sheep serum, 1% BSA, 1% DMSO, 0.1% Tween-20) in PBS. Na+/K+
ATPase was detected using anti-α6F antibody (kindly provided by S. Tsukita) at
1:100 dilution in blocking buffer for 1 h at room temperature. Embryos were
washed with PBT 4 times for 10 min each and then incubated with biotin
conjugated goat–anti-mouse secondary antibody (1:1000) for 1 h at RT. After
several extensive washing, the embryos were incubated with Cy3–streptavidin
(1:1000 dilution) for 1 h at RT. After washing with PBT, the embryos were
examined and using a fluorescence dissecting microscope (Leica FLIII).Wheat germ agglutinin
Embryos were fixed in 4% paraformaldehyde for 2 h to overnight. Fixed
embryos were incubated in 100% acetone at −20 °C for 20 min then returned to
PBT and permeabilized with 120 μg/ml proteinase K in (PBS and 0.1% Tween-
20, PBT) for 35 min at room temperature. Goblet cell mucin was detected by
incubation with rhodamine-conjugated wheat germ agglutinin (1:100 dilution in
PBS and 0.1%Tween-20) (Vector Laboratories) overnight at 4 °C. Embryoswere
washed with PBT 4 times at 10 min each then photographed by fluorescence
microscopy.
Alkaline phosphatase
Embryos were fixed in 4% paraformaldehyde for 2 h to overnight. For
alkaline phosphatase staining, embryos were incubated with 100% acetone for
30 min at −20, washed with NTMT buffer [0.1 M Tris–HCl (pH 9.5), 50 mM
MgCl2, 0.1 M NaCl and 0.1% Tween-20] 2 times for 10 min each before they
were incubated with the reaction substrate, NBT and BCIP (Roche). For
histological analysis, embryos were embedded in JB-4 (Polysciences) and
sectioned as described above.
Alcian blue staining
Embryos fixed in PFAwere washedwith PBS followed bywashingwith 20%
acetic acid in ethanol. Alcian blue (Sigma Cat# A-3157) at 0.1% (20% acetic acid
and 80% ethanol) was preformed as described in Schilling et al. (1996).
Western blot
Embryos were collected at 52 or 72 hpf, homogenized in sodium dodecyl
sulfate lysis buffer (62.5 mM Tris–HCl, pH 6.8, 25% glycerol, 5% β-
mercaptoethanol, 2.5% sodium dodecyl sulfate). Total extract was boiled for
6–7 min then centrifuged at 14,000×g for 10 min at room temperature.
Supernatant (about 20–35 μl of total extract per lane) was resolved by SDS-
PAGE and analyzed byWestern blot using anti-S6K at 1:10,000 dilution (Sigma)
then stripped and reprobed with anti-T389 phospho-S6K at 1:200 dilution (Santa
Cruz). Samples were normalized to the total S6K.Results
Sequence and alignment of the zebrafish ortholog of TOR
(ztor)
The TOR protein is conserved among all eukaryotes
(Abraham, 2004); thus we expected to identify at least one
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(tblastn) of the zebrafish genome assembly (zv5) against human
or mouse mTOR protein identified a single locus on chromo-
some 8 predicted to encode a protein nearly 90% identical to
mammalian orthologs, consistent with a conserved function
across eukaryotic species. The current genomic assembly
contains a gap that corresponds to the middle third of the
protein. Guided by the predicted exon sequences, we bridged
this gap via RT-PCR and 5′RACE to assemble a full-length
cDNA sequence 8.5 kb in length (accession # DQ666026).
Alignment of the predicted protein with other TOR orthologs
indicates the same domain structure, including the HEAT
repeats, FAT domain, FKBP–rapamycin binding domain, and a
highly conserved kinase domain near the C-terminal (Fig. S1).
ztor expression
As an initial step to examine the role of ztor during
development, we determined its expression pattern by whole-
mount in situ hybridization (Fig. 1). This revealed ubiquitous
expression between the 1-cell and 24 hpf stages. Between 24
and 48 h, there is a general decline in expression in most of theFig. 1. ztor expression during embryonic and larval development. Panels A–G:
whole-mount in situ hybridization to ztor shown in dorso-lateral view with head
to the left. Panels H and I: histological sections of embryos shown in panels C
and D, respectively. Prior to 24 hpf, ztor is expressed ubiquitously (A). Ztor
expression then recedes in a caudal-to-cranial fashion between 24 and 48 hpf
with expression remaining in the gut and the head (B and C). Ztor expression
transiently increases in the gut tube between 48 and 57 hpf (D) and then declines
in the gut, remaining detectable in the head thereafter (E–G). Cross-sections of
48 and 57 hpf embryos show ztor expressed in the gut tube epithelium (H and I).
Dashed lines outline the gut epithelium, solid line delineates mesenchyme from
yolk. Original magnification: A–F, 40×; G and H, 200×. Abbreviations: en,
endoderm; g, gut; e, epithelium; m, mesenchyme; y, yolk.body in a caudal to cranial wave, with persistence in the head,
particularly in the brain, eyes and branchial arches (Figs. 1A–
C). Between 48 and 72 hpf, there is a transient increase in ztor
expression in the digestive tract and in the neural tube, peaking
around 57 hpf (Fig. 1D). After 72 hpf the gut-specific
expression declines and thereafter remains barely detectable.
A positive control probe (ifabp) routinely gave robust signal,
making poor probe penetration an unlikely possibility (not
shown). After 96 hpf, ztor expression persists in the head and
the eyes (Figs. 1F and G). Histological sectioning of the 48 and
57 hpf embryos revealed that most of the intestinal staining is
within the epithelium (Figs. 1H and I) as compared to the
mesenchyme. Thus, transcriptional regulation of ztor may play
a role in regulating epithelial cell growth and division.
Rapamycin exerts a specific effect on the digestive tract
To evaluate the function of ztor during development we
treated zebrafish embryos with the TOR inhibitor, rapamycin.
Increasing concentrations between 10 nM and 100 nM gave
increasingly pronounced effects, but rapamycin concentrations
ranging from 200 nM to 10 μM rapamycin gave comparable
results (data not shown). Hence, we used 400 nM as the
standard treating concentration for the experiments described in
the remainder of this paper, unless otherwise specified. We
repeated many of the experiments using the rapamycin analog
RAD-001 and observed identical effects (data not shown).
We first analyzed the effects of rapamycin treatment on live
zebrafish embryos beginning at the 1-cell stage up to 5 days
post-fertilization (dpf) (Fig. 2A). During the first 72 h,
rapamycin induced a mild, general developmental delay. To
objectively assess its extent, we measured the head–trunk angle
as a function of chronological age (Fig. S2). Rapamycin
treatment shifted the curve to the right, but the shape of the
curve was nearly identical to control, supporting the interpreta-
tion that the embryos were delayed, but not arrested.
Normally, after 72 hpf the intestine becomes an increasingly
prominent structure, occupying the ventral third of the body by
5 dpf. But in the rapamycin-treated larvae the gut tube was
barely detectable at 5 dpf. To better visualize rapamycin’s
effects on digestive organ growth, we treated embryos from the
Gut-GFP transgenic line, which expresses enhanced green
fluorescent protein (EGFP) in the gut, liver and pancreas (Ng
et al., 2005). We confirmed that the early morphogenesis of the
digestive tract up to 72 hpf was delayed by rapamycin, but
patterning of the digestive tract was otherwise normal (Fig.
2B). In particular, the liver and pancreas bud from the gut tube
at the expected A–P position, but they are clearly smaller than
in control fish. Thus, rapamycin appears to affect the
outgrowth of the digestive organs in addition to the intestine
proper.
A well-established target of TOR kinase is p70 S6 kinase
(S6K); the phosphorylation of S6K at threonine 389 is sensitive
to rapamycin (Fingar et al., 2002). We analyzed the effect of
rapamycin on S6K phosphorylation by Western blot of 52 hpf
embryo extracts (Fig. 2C). Using phospho-T389-specific anti-
body, we noted a substantial decrease in response to rapamycin
Fig. 2. Effect of rapamycin on zebrafish embryonic development. Zebrafish embryos were treated with 400 nM rapamycin continuously beginning at 1-cell stage and
photographed at the indicated developmental stages. (A) Embryos treated with rapamycin are shown live. Up to 74 hpf rapamycin induced a generalized
developmental delay. However, by 120 hpf most structures in the rapamycin-treated embryos ultimately developed, with the notable exception of the digestive organs.
Yolk absorption was also significantly delayed. (B) Fluorescence microscopy of live Gut-GFP transgenic embryos; green fluorescence marks the endoderm. Prior to
72 hpf, the size of the organs is concordant with the developmental stage, which is known to be delayed as seen in panel A. Embryos treated with rapamycin show a
marked deceleration of digestive system growth after 72 hpf. (C) Western blot analysis of phospho-389-S6 kinase and total S6 kinase in rapamycin and RAD-001-
treated zebrafish embryos. Embryos were treated at 24 hpf with 400 nM of the indicated drug and extract collected at 52 hpf. The blot shows virtually complete
inhibition of TOR kinase by this criterion. Abbreviations: SB, swim bladder; L, liver; p, pancreas; g, gut; (g), approximate position of gut, but not discernible. Original
magnification: A, B 40×.
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inhibition of a known downstream target of TOR in treated
zebrafish.
During larval development, other structures outside the
gastrointestinal tract developed relatively normally despite
treatment with rapamycin. Vasculogenesis (including subintest-
inal vessels) appears normal based on alkaline phosphatase
staining (Fig. 3A, a and b). The branchial arches appeared
essentially normal by Alcian blue staining (Fig. 3A, c and d),
and the pronephric epithelium (visualized with the α6F
antibody) appeared normal as well (Fig. 3A, e and f). Heart
function and circulation were not perceptibly affected byrapamycin based on observations of live embryos (not shown).
Further incubation with rapamycin up to 9 dpf revealed no
further growth of the intestine (Fig. 3B), confirming its
developmental arrest at an earlier stage.
Morphometric analysis of developing intestine in
rapamycin-treated embryos
Intestinal morphogenesis involves a concerted series of
changes in the size and architecture of the epithelial cells that
line the gut tube. To evaluate the effect of rapamycin on
morphogenesis, we performed histological cross-sectioning at 3
Fig. 3. (A) (a, b) Whole-mount staining for alkaline phosphatase in rapamycin-
treated embryos demonstrated normal blood vessel morphogenesis; (c, d) Alcian
blue staining demonstrated that branchial arch formation was not significantly
affected by rapamycin, though the size of the cranium and jaw was slightly
smaller in treated embryos. Numerals denote the branchial arches; (e, f)
immunofluorescence staining for α6F subunit of Na/K ATPase reveals that the
pronephric ducts are structurally normal in rapamycin-treated larvae. (B)
Sagittal sections of 9 dpf larvae stained with H&E, control and treated with
rapamycin, demonstrating the disproportionate and enduring effect of rapamycin
on gut development relative to the rest of the embryo. Abbreviations: BA,
branchial arches; SB, swim bladder; isv, intersomitic vessels; siv, subintestinal
vessels; pd, pronephric duct; L, liver; g, gut; y, yolk. Original magnification: A,
40×; B, 100×.
Fig. 4. Morphometric analysis of intestinal growth and morphogenesis in rapamy
untreated or treated with rapamycin, at the indicated stage. Morphometric analysis is s
average number of epithelial cells composing the gut tube in a single section. Ce
measurements; ht:w is the ratio of average epithelial cell height to average width. Each
P axis, from 6 embryos (12–18 sections). There are minimal effects on growth bef
sensitivity to rapamycin, whereas the hindgut is less affected. (B) Embryos injected at
section of the midgut stained with H&E at 6 dpf. Bar graphs summarized the morph
discrete stage (about 70–72 hpf) at which the gut is sensitive to rapamycin treatmen
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regions. We analyzed samples by three criteria: cell number, cell
size and columnarity (height-to-width ratio) (Fig. 4A, Figs. S3
and S4). To ensure the validity of comparisons between
embryos, we chose sections relative to fixed points along the
A–P axis using internal landmarks (i.e. pneumatic, duct, bile
duct, etc.) as described in detail in Materials and methods. The
results for the midgut are described below since this area
displayed the most pronounced effects on growth and
morphogenesis.
At 48 hpf, we found few differences between control and
treated intestine with regard to cell number or size. The gut tube
contained a central lumen (smaller in the rapamycin-treated
embryos), and the cell morphology was consistent with
undifferentiated intestine (Fig. 4A, 48 hpf). At 74 hpf,
rapamycin-treated embryos began to diverge from the controls
along all three parameters. The gut tube was smaller due to the
combined effect on cell number and size. Furthermore, the cell
morphology was more cuboidal in the rapamycin-treated gut,
and this was reflected by the average height-to-width ratio (2.2
in control vs. 1.2 in treated) (Fig. 4A, 74 hpf).
To account for the decreased cell number in the rapamycin-
treated embryos, we measured the proliferation rate in the
intestinal epithelium by BrdU incorporation (Fig. S4A). At
51 hpf, 27.2±5.1% of the cells were BrdU positive in the
control (n=5 embryos), and 22.3±7.4% were positive in the
rapamycin-treated embryos (n=5 embryos) (p>0.05). At
72 hpf, 33.9±5.3% of the cells were BrdU positive (n=5
embryos), compared to 25.6±3.7% in the rapamycin-treated
embryos (n=9) (p<0.05). We did not detect any apoptosis by
histological criteria or by TUNEL assay in the intestinal
epithelium of control or treated embryos (not shown), whereas
the TUNEL assay was positive in the anus of both control and
treated larvae (internal positive control). Thus, we attribute the
decreased cell number in the epithelium to a decrease in the cell
proliferation rate. The difference between controls and treated
was not statistically significant at 51 hpf, but was significant at
72 hpf. This would suggest that the effect of rapamycin varies
across this developmental time frame.
At 96 hpf, the effect of rapamycin became much more
pronounced. Normally at this stage the epithelial cells adopt
the signature features of differentiated enterocytes: columnar
morphology, basal nuclear localization and a distinct, eosino-
philic apical cytoplasm. In the rapamycin-treated animals, the
gut epithelial cells were less numerous and qualitatively
different from controls. The nuclei were pleiomorphic and
their location was less uniformly basal. The cells were smaller
and less columnar, resembling normal epithelial cells at a muchcin-treated larvae. (A) Cross-sections of the midgut stained with H&E, either
ummarized in the bar graphs to the right of the micrographs. Cell number refers to
ll size is expressed in μm3and is derived from average cell width and height
measurement was derived from 2 to 3 sections at a similar location along the A–
ore 72 hpf. Then, at 96 hpf the foregut and midgut show the most pronounced
the indicated stage with 400 nM rapamycin; live photo and corresponding cross-
ometric analysis done as above (*p<0.05). Taken together, A and B suggest a
t. Original magnification of micrographs, 200×.
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This effect is not a transient delay since the appearance did not
change substantially even by 9 dpf (Fig. 3B).We performed a similar morphometric analysis on the
anterior and posterior gut and found that the effects were
qualitatively similar (Fig. S3). The data from all three locations
Fig. 5. Effect of rapamycin on intestinal cell differentiation. (A and B)
Histochemical staining for alkaline phosphatase shows enzyme expression and
localization to the apical aspect of the epithelial cells. Expression appears to be
decreased in the treated embryos, particularly on the ventral epithelium. (C, D)
Whole-mount in situ hybridization for the enterocyte marker villin is specific to
the intestinal epithelium and is similar in treated and untreated embryos. (E, F)
Whole-mount in situ hybridization for the enterocyte marker ifabp shows robust
expression in controls and barely detectable expression in rapamycin-treated
embryos. (G, H) Lateral view of whole-mount stained embryos for goblet cell
mucin using rhodamine-conjugated wheat germ agglutinin (WGA). Staining
appears to be virtually undetectable in the posterior gut of treated embryos. Gut
is outlined by black and white lines (in panels F and H, respectively). Original
magnification is 100× in panels A and B, 40× in panels C–H.
508 K. Makky et al. / Developmental Biology 303 (2007) 501–513are integrated in Fig. S4B, which depicts intestinal growth in a
schematic, yet quantitative format. In the untreated fish, the
anterior and midgut sections show the highest degree of
expansion from 48 to 96 hpf. These regions were also the most
sensitive to rapamycin, consistent with a critical role for TOR
signaling in their growth and morphogenesis. The posterior gut
was also affected by rapamycin, but to a much lesser degree.
The stage at which arrest occurred corresponded morpholo-
gically to about 72 hpf, which is when the intestine is
undergoing a rapid growth phase (Wallace et al., 2005). The
timing of this effect was shortly after the transient upregulation
of ztor expression shown in Fig. 1, consistent with a critical role
for TOR signaling at this time. To better define the window for
rapamycin sensitivity, we treated larvae with rapamycin at
different times between 48 and 77 hpf and analyzed the
phenotype at 6 dpf (Fig. 4B). The results showed an inhibition
of intestinal growth in the larvae treated at 48 hpf, affecting both
cell number and morphology. This effect was similar to
treatment at 24 hpf (compare Fig. 4A, 96 hpf, treated at 24 h
vs. Fig. 4B, 6 dpf treated at 48 h). Between 72 and 77 hpf,
susceptibility to rapamycin decreased precipitously. Treatment
at 72 hpf resulted in a mild decrement in cell number, but a more
pronounced effect on cell morphology. At 77 hpf, there were no
discernible effects of rapamycin, despite the fact that the
intestine undergoes a substantial amount of growth between
77 hpf and the time of analysis at 6 dpf. Thus, we have
identified a developmental window during which TOR signal-
ing is required for intestinal development.
Rapamycin affects epithelial cell differentiation
Since rapamycin interferes with intestinal morphogenesis,
we wanted to know if cell type differentiation was affected as
well. We tested the expression and localization of the enterocyte
marker alkaline phosphatase and found that rapamycin induced
a discernible decrease in brush border staining, particularly on
the ventral aspect of the gut (Figs. 5A and B). However, the
stain was properly localized to the apical aspect of the cells.
Interestingly, villin expression was comparable in control and
treated intestine (Figs. 5C and D), but the enterocyte marker
intestinal fatty acid binding protein (ifabp) was substantially
reduced in rapamycin-treated larvae (Figs. 5E and F). These
results indicate that enterocyte specification is not blocked by
rapamycin, but differentiation is blocked at a stage delineated
by the expression of ifabp.
We assessed for the presence of goblet cells using
fluorescently labeled wheat germ agglutinin and detected no
signal in the gut of rapamycin-treated embryos (Figs. 5G and
H). Thus, rapamycin blocked the later differentiation of
epithelial cells consistent with a critical role for TOR signaling
in the intestine’s developmental program.
TOR inhibition underlies the effect of rapamycin on intestinal
development
To our knowledge, the only documented biological activity
of rapamycin is inhibition of TOR signaling (Edinger et al.,2003). Nevertheless, we sought to verify that the effects of
rapamycin on intestinal development were indeed via TOR
inhibition. Rapamycin is known to inhibit TOR by forming a
ternary complex with FK506 binding protein (FKBP). The
drug FK506 also binds FKBP and competes with rapamycin,
but this complex does not inhibit TOR. Accordingly, if the
effect of rapamycin on intestinal development is indeed due to
inhibition of TOR, then FK506 should be able to antagonize
rapamycin’s effect. When we performed this experiment by
comparing embryos treated continuously with rapamycin in the
presence and absence of FK506, we saw no discernible
differences (not shown). However, when we treated embryos
with rapamycin between 0 and 3 hpf, then replaced the
medium with either no drug or FK506, we observed that post-
treatment with FK506 mitigates the effect of rapamycin in a
dose-dependent manner (Fig. 6A). We performed Western blot
analysis to detect phospho-389 S6 kinase in response to these
treatments (Figs. 6B and C). In the absence of FK506, we
noted a 30% reduction of the phospho-S6/total S6 kinase ratio
(normalized to control). Addition of FK506 resulted in no
changes in this ratio. These data support the interpretation that
rapamycin affects intestinal development via the canonical
mechanism for TOR inhibition.
Fig. 7. Morpholino-mediated knockdown of TOR. 1- to 4-cell stage embryos
were injected with morpholino oligonucleotide directed to a predicted splice site
in the ztor transcript. (A) RT-PCR showed a reduction in ztor expression in
conjunction with the appearance of an aberrant splice product at 48 and 72 hpf.
By DNA sequencing, this product was confirmed to contain a large intronic
fragment derived from the genomic sequence. (B) Upper panels show live larvae
at 96 hpf, with liver outlined by solid line, gut tube outlined by dashed line. Both
liver and gut are several-fold smaller in TOR morphant. The rest of the larva
(e.g. head, somites) appears relatively normal. Lower panels show histological
cross-sections through the midgut stained with H&E. TOR morphants show
hypoplastic intestine with defective epithelial morphogenesis; note lack of folds
and cuboidal epithelial morphology in morphants, similar to the effect of
rapamycin. (C) Whole-mount in situ hybridization for ifabp demonstrating
substantially lower expression in TOR morphant, indicating a differentiation
defect similar to the effect of rapamycin. Original magnification panel B (live
embryos) and panel C is 40×; panel B (histology) is 200×. Abbreviation: g, gut.
Fig. 6. Rapamycin acts through TOR inhibition. (A) FK506 rescues the
rapamycin phenotype. Shown are live and sectioned 96 hpf embryos stained
with H&E treated as follows: (a) no treatment; (b) rapamycin 0–3 hpf, no
FK506; (c) rapamycin 0–3 hpf, then 0.7 μM FK506 3–96 hpf; (d) rapamycin
0–3 hpf, then 1.5 μM FK506 3–96 hpf. Comparing Ab to Ac and Ad shows that
addition of FK506 attenuates the intestinal defect in a concentration dependent
fashion. Magnification: live images are 40× and sections are 400×. (B) Western
blot analysis of S6 kinase phosphorylation. Extracts from control and
rapamycin-treated embryos were analyzed for total S6K and T389 phospho-
S6K in the absence and presence of FK506. (C) Densitometric analysis of band
intensities in panel B normalized for total S6 kinase shows a 30% reduction of
phospho-S6 kinase in rapamycin-treated embryos. FK506 treatment blocks this
effect.
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Using a morpholino targeting a splice junction upstream of
the TOR kinase domain, we effected a knockdown of ztor (Fig.
7A). This morpholino resulted in a relatively normal appearing
Fig. 9. Developmental expression of raptor and rictor. Whole-mount in situ
hybridization for raptor and rictor shows a similar pattern up to 34 hpf, after
which the patterns diverge. Both genes are expressed in the head and the
endoderm earlier then raptor is selectively upregulated in the digestive organs at
48 and 72 hpf. Raptor then declines at 96 hpf. Rictor remains expressed in the
head, but is not expressed later in the digestive tract. Original magnification 40×
(all panels). Abbreviations: e, endoderm; L, liver; p, pancreas; g, gut. Dashed
lines indicate the position of the digestive organs.
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poorly differentiated (Fig. 7B). The block in differentiation is
reflected by the reduction in ifabp expression in the ztor
morphants (Fig. 7C). Sequencing of the aberrant RT-PCR
product demonstrated that the morpholino induced utilization of
a cryptic splice donor that interrupted the mRNA with several
kb of intronic sequences. Targeting a different intron–exon
junction gave a similar phenotype (not shown).
We also tested the functional role of s6k by morpholino-
mediated knockdown. Splice-directed morpholinos induced a
reduction in wild-type s6k message (Fig. 8A) and induced an
appearance similar to the rapamycin-treated embryos: mildly
delayed, but with smaller, poorly differentiated gut tube (Fig.
8B). Intestinal epithelial folds were absent, and the cells were
less columnar with pleimorphic nuclei located at random
stations with respect to the apical–basal axis. These results are
consistent with a role for S6K in mediating intestinal growth
and morphogenesis.
Intestinal development requires TOR complex 1
Two biochemically distinct TOR-containing complexes have
been described previously. TOR complex 1 (TORC1) is
rapamycin-sensitive and contains the protein Raptor (Hara et
al., 2002; Kim et al., 2002), whereas TORC2 is rapamycin-
insensitive and contains the protein Rictor (Sarbassov et al.,
2004). The observation that rapamycin has a disproportionateFig. 8. Morpholino-mediated knockdown of p70 S6 kinase. 1- to 4-cell stage
embryos were injected with morpholino directed to a predicted splice site in the
p70 S6 kinase transcript. (A) RT-PCR shows reduction of normal splice product
in control and decreased product in morphant embryos, with aberrant splice
products in the morphants. (B) Shown are live embryos and corresponding
histological cross-sections through the midgut of the control and morphant
embryos. Knockdown of S6K results in a normally formed embryo with a
specific defect in the digestive organs; histology reveals a poorly differentiated,
featureless epithelium with cuboidal cellular morphology, similar to the TOR
morphant and rapamycin treatment. Original magnification: 200×.effect on digestive development suggested that TORC1 is
essential to this developmental process. Whereas TOR knock-
down would be expected to affect both TORC1 and TORC2, the
effect was similar to that of rapamycin treatment. This would
suggest that TORC2 is not essential to this stage of intestinal
development.
As an initial test of this idea, we identified the zebrafish
orthologs and determined the developmental expression pattern
for both raptor and rictor by whole-mount in situ hybridization
(Fig. 9). Although both genes were expressed in the head and
endoderm at 34 hpf, only raptor is expressed in the nascent
digestive organs at 48 hpf and 72 hpf. In contrast, rictor
expression was nearly undetectable in these structures.
To further evaluate the respective roles of TORC1 and
TORC2 during development, we performed morpholino-
mediated knockdown of both raptor and rictor (Fig. 10).
Knockdown of raptor phenocopied rapamycin treatment and
the ztor and s6k morphants, featuring a smaller gut tube and
poorly differentiated epithelium. In contrast, knockdown of
rictor had minimal effects on intestinal growth or morphogen-
esis. These data support an essential role for TORC1 in
regulating intestinal development; TORC2, in contrast, appears
not to play a critical role at this stage.
Discussion
Here we report the initial broad examination of TOR
signaling during zebrafish development. We found that
rapamycin had an unexpectedly mild effect on early embryonic
Fig. 10. TOR complex 1 regulates intestinal growth. Splice-directed morpholinos to either raptor or rictor were microinjected into 1- to 4-cell stage embryos. (A) RT-
PCR demonstrated a significant reduction of raptor at 24 hpf, whereas both messages were substantially reduced at 48 hpf. (B) Live embryos at 96 hpf and
corresponding cross-sections of the midgut stained with H&E show a substantial effect on gut morphology in the raptormorphant as compared to the rictormorphant.
In the raptor morphant the gut tube is smaller and the cells are smaller and less columnar than in the rictor morphant. In contrast rictor knockdown had a negligible
effect on intestinal development. Original magnification: 200×.
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development. We also analyzed the effects of morpholino-
mediated knockdown of TOR pathway components, and
together the data support an essential role for TORC1 in the
elaboration of a fully differentiated intestinal epithelium.
TORC1 has been postulated to serve as a metabolic checkpoint,
regulating cell growth in response to nutrient availability and
growth factor signaling (Kim et al., 2002). Thus, in characteriz-
ing the defect induced by TORC1 inhibition, we have
delineated a development step subject to regulation by this
checkpoint apparatus.
Transcriptional regulation of TOR and raptor
Previous reports have described TOR expression as
ubiquitous (Leevers and Hafen, 2004; Long et al., 2002; Sabers
et al., 1995). The pattern we observed was both spatially and
temporally dynamic, featuring a transient increase in the
intestinal epithelium at about 60 hpf. Interestingly, the
expression pattern for raptor, a defining component of the
TORC1 complex, displayed a spatio-temporal pattern similar to
ztor in the digestive tract between 48 and 72 hpf. TORC1
signaling thus appears to be regulated, at least in part, at the
level of transcription of its key components. This seems logical
since at 60 hpf the gut tube is poised to undergo a major growth
spurt; increased ztor and raptor expression may further amplify
upstream signals that are known to activate TOR (growth
factors, nutrients) to promote tissue expansion during this
developmental period.Organ and stage specificity of rapamycin effects and TORC1
function
In embryos treated from the 1-cell stage, the most enduring
and pronounced effects of rapamycin are on the zebrafish
digestive tract. Why these tissues displayed a disproportionate
sensitivity to rapamycin is not clear since other tissues such as
the brain also express TOR and experience substantial growth
during the same time frame. A review of the literature reveals
unexplained differences in rapamycin sensitivity between
species and between tissues within sensitive species. For
example, in S. cerevisiae, cell growth and division are sensitive
to rapamycin (Heitman et al., 1991), whereas C. elegans
displayed no sensitivity to rapamycin treatment (Long et al.,
2002). In Drosophila, rapamycin treatment slowed develop-
ment during early larval stages, eventually leading to lethality
(Oldham et al., 2000) and rapamycin sensitivity was noted to be
more pronounced in endoreplicative structures such as the
salivary gland (Zhang et al., 2000). In the mouse, treating the
E3.5 embryo with rapamycin inhibited proliferation of
trophoblast more than the inner cell mass (Murakami et al.,
2004), and later in mouse embryogenesis TOR is broadly
required for proliferation (Hentges et al., 2001).
Perhaps the best context for assessing rapamycin sensitivity,
owing to the sheer variety of cell phenotypes, is in cancer cells
(Vignot et al., 2005). Of all variables examined, increased
sensitivity to rapamycin seems to correlate best with the
oncogenic inactivation of PTEN tumor suppressor, which leads
to elevated signaling via phosphatidyl inositol 3-phosphate
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means available for cells to engage in growth and proliferation,
the PI3P route renders the cell particularly dependent on TOR
signaling. Hence, these cells display increased susceptibility to
rapamycin. Analogously, increased signaling through the PI3K
pathway in the developmental context may likewise be a critical
determinant for rapamycin sensitivity. The intestine is known to
require epidermal growth factor and insulin-like growth factor
for normal growth, among other factors that act through the
PI3K pathway (Abud et al., 2005; Dignass and Sturm, 2001).
The tissue distribution and timing of the effects of rapamycin
may thus be a consequence of the developmental activation of
the PI3K pathway and the extent to which TORC1 transmits
those signals to the cellular machinery.
In a recent report, Goldsmith et al. (2006) demonstrated
differential rapamycin sensitivity in adult versus juvenile fish
in the caudal fin. They found that allometric growth in juvenile
fish was rapamycin-resistant/TOR-independent, but in the adult
fish, isometric fin growth was rapamycin-sensitive/TOR-
dependent. These results provide additional evidence for the
idea that TOR dependence is not a uniform feature of all
growth phenomena. Dependence on TOR signaling for growth
may signify a high degree of reliance on nutrient sensing for
growth control, for reasons that are yet to be discerned. The
relatively mild effect of rapamycin on early embryonic
development in zebrafish may reflect similar differences in
TOR dependence. Likewise, the transition from TOR-depen-
dent to TOR-independent growth in the developing intestine
between 72 and 77 hpf may arise from a transition in growth
control mechanisms.
The developmental role of TORC1
The morphogenic sequence for intestinal development in the
zebrafish has been described in detail previously (Ng et al.,
2005; Wallace et al., 2005) and can be divided conceptually into
two stages. In the first stage, the primitive gut tube is fashioned
from the endoderm between 32 and 40 hpf by the formation of
junctional complexes at the nascent apices of the epithelial cells
(Horne-Badovinac et al., 2001). The second stage of intestinal
morphogenesis occurs between about 60 and 80 hpf. During this
phase, the epithelium adopts a columnar morphology, increases
several-fold in size, forms folds and diversifies into absorptive
and secretory subtypes (Wallace et al., 2005). TORC1 appears
to be selectively required for the later stages of intestinal
development based on the observed defects in growth,
morphogenesis and cell differentiation caused by its inhibition.
Villin expression is initiated in the epithelium at about 70 hpf
(ANM, unpublished results) and rapamycin treatment had no
effect on its expression. However, rapamycin-treated embryos
failed to fully activate ifabp by 96 hpf, even though expression
is initiated between 72 and 84 hpf (Andre et al., 2000). Arrest of
enterocyte differentiation between the onset of villin and ifabp
expression thus delineates the requirement for TORC1 signaling
to the developmental interval between 70 and 84 hpf. The gut
specificity of this requirement is supported by the failure of
rapamycin-treated larvae to elaborate goblet cells, whereas thebranchial arches and swim bladder continue to grow beyond
96 hpf.
By treating larvae with rapamycin at different times, we
demonstrated that intestinal development transitions to a
TORC1-independent mechanism between 72 and 77 hpf.
Taken together with the marker expression data, this allows us
to further narrow the window of TOR dependence to around
70 hpf.
We hypothesize that TORC1 may be serving as a permissive
regulator of intestinal development at this juncture, when the
primitive epithelium must commit to a dedicated program of
growth, morphogenesis and differentiation. This would expand
the repertoire of TORC1 function, most often invoked as a
controller of cell growth and proliferation (Wullschleger et al.,
2006). Recent work in the setting of neuronal differentiation in
Drosophila points to a role for TOR in the coordination of
developmental timing (Bateman and McNeill, 2004). The data
presented here suggest that a similar role for TOR may be
operative in the vertebrate digestive tract. This would suggest
that TORC1 is required during a particular developmental
window, and the timing of which may be reflected in the
transient expression of tor and raptor in the intestine. It is not
clear how directly TORC1 may be communicating with the
intestine’s developmental program. It may be required to
activate a cascade of gene expression that leads to a differen-
tiated state or to achieve an organ size threshold required to
activate morphogenesis.
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